First Time Loading...

Beijing Strong Biotechnologies Inc
SZSE:300406

Watchlist Manager
Beijing Strong Biotechnologies Inc Logo
Beijing Strong Biotechnologies Inc
SZSE:300406
Watchlist
Price: 17.63 CNY -1.01%
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

5.2B
+4%
Assets
Growth Rates:
1 Year
+12%
3 Years
+31%
5 Years
+178%
7 Years
+252%
10 Years
-
1.5B
+5%
Liabilities
Growth Rates:
1 Year
+8%
3 Years
+89%
5 Years
+793%
7 Years
+1 646%
10 Years
-
3.7B
+4%
Equity
Growth Rates:
1 Year
+14%
3 Years
+16%
5 Years
+119%
7 Years
+168%
10 Years
-

Balance Sheet Decomposition
Beijing Strong Biotechnologies Inc

5.2B
Assets
1.5B
Liabilities
5.2B
Assets
1.5B
Liabilities
Current Assets 2.3B
Cash & Short-Term Investments 863.8m
Receivables 1.2B
Other Current Assets 261.8m
Non-Current Assets 2.8B
Long-Term Investments 472.7m
PP&E 555.2m
Intangibles 1.7B
Other Non-Current Assets 80.5m
Current Liabilities 297.1m
Accounts Payable 73.3m
Accrued Liabilities 98.5m
Short-Term Debt 10.9m
Other Current Liabilities 114.5m
Non-Current Liabilities 1.2B
Long-Term Debt 1.1B
Other Non-Current Liabilities 22.4m

Balance Sheet
Beijing Strong Biotechnologies Inc

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
645
698
792
683
480
226
577
383
328
712
Cash
0
0
0
0
0
0
0
383
328
712
Cash Equivalents
645
698
792
683
480
226
577
0
0
0
Short-Term Investments
0
0
0
0
0
0
25
10
325
152
Total Receivables
218
296
368
459
532
634
853
1 056
1 125
1 209
Accounts Receivables
202
283
351
425
447
552
746
917
1 010
1 101
Other Receivables
15
13
17
34
85
82
107
138
115
108
Inventory
83
94
97
120
114
150
247
252
220
230
Other Current Assets
24
47
36
21
146
51
69
41
68
32
Total Current Assets
968
1 134
1 293
1 282
1 272
1 060
1 772
1 741
2 067
2 334
PP&E Net
70
119
163
181
234
273
324
366
439
555
PP&E Gross
70
119
163
181
234
273
324
366
439
555
Accumulated Depreciation
37
46
56
72
85
101
153
182
181
216
Intangible Assets
4
4
4
5
6
7
72
74
66
60
Goodwill
0
0
0
282
282
282
1 673
1 673
1 673
1 673
Note Receivable
0
0
0
9
6
14
21
33
15
26
Long-Term Investments
0
0
0
0
0
0
0
398
301
473
Other Long-Term Assets
2
5
11
20
66
519
103
35
53
54
Other Assets
0
0
0
282
282
282
1 673
1 673
1 673
1 673
Total Assets
1 045
N/A
1 262
+21%
1 471
+17%
1 779
+21%
1 865
+5%
2 154
+16%
3 964
+84%
4 320
+9%
4 613
+7%
5 176
+12%
Liabilities
Accounts Payable
21
23
22
29
33
24
42
47
37
73
Accrued Liabilities
6
10
11
18
16
10
71
80
86
98
Short-Term Debt
0
0
0
0
0
84
0
163
81
11
Current Portion of Long-Term Debt
0
0
0
0
0
0
38
194
2
1
Other Current Liabilities
22
47
45
125
103
38
91
123
91
113
Total Current Liabilities
49
79
78
172
152
156
243
608
298
297
Long-Term Debt
0
0
0
0
0
0
262
767
1 018
1 132
Deferred Income Tax
0
0
0
1
1
1
13
11
10
8
Minority Interest
0
0
0
0
0
0
226
39
2
3
Other Liabilities
8
7
5
75
10
26
23
20
19
17
Total Liabilities
57
N/A
87
+51%
83
-4%
249
+199%
163
-35%
183
+13%
766
+318%
1 445
+89%
1 342
-7%
1 451
+8%
Equity
Common Stock
124
250
500
502
502
502
589
589
589
588
Retained Earnings
503
686
883
1 006
1 231
1 488
1 526
1 873
2 203
2 668
Additional Paid In Capital
360
266
26
52
59
64
1 158
488
392
400
Treasury Stock
0
27
21
30
90
83
75
75
93
110
Other Equity
0
0
0
0
0
0
0
1
180
177
Total Equity
987
N/A
1 175
+19%
1 388
+18%
1 530
+10%
1 702
+11%
1 971
+16%
3 198
+62%
2 874
-10%
3 271
+14%
3 725
+14%
Total Liabilities & Equity
1 045
N/A
1 262
+21%
1 471
+17%
1 779
+21%
1 865
+5%
2 154
+16%
3 964
+84%
4 320
+9%
4 613
+7%
5 176
+12%
Shares Outstanding
Common Shares Outstanding
498
498
498
502
502
502
589
589
589
588

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.